



ASX: **NRT**
NASDAQ: **NVGN**



30-second Overview

2014

Novogen is an Australian biotechnology company listed on both the Australian Securities Exchange (NRT) and NASDAQ (NVGN).

Novogen owns two proprietary drug technology platforms that are first-in-class and which the Company believes will be the foundation that will enable us to grow into a major global biopharmaceutical force.

Both technologies target essential functions, that lie at the heart of cells behaving abnormally. These essential functions are present across a wide range of degenerative diseases, including cancer, genetic disorders, and autoimmune diseases.

These are entirely novel drug targets and Novogen believes addressing them will revolutionize the treatment of many of the common diseases affecting our community and for which no curative treatments currently exist.

The first of our technologies is a family of small molecules known as super- benzopyrans (SBPs).

SBPs regulate the function of tissue stem cells, the first molecules ever found to do so.

This ability is being manipulated to produce drugs that have a wide range of effects. These range from killing cancer stem cells (the cause of cancer), to having the opposite effect and promoting the activity of stem cells in disease states such as muscular dystrophy, motor neurone disease and Alzheimer's in order to restore normal function.

The second is our ATM technology. This targets the microfilament component of a cell's cytoskeleton. The target of this new class of drug is a specific isoform of tropomyosin that is implicated in the function of cancer cells and also in cells involved in certain autoimmune diseases such as ulcerative colitis.